Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Determinants of early mortality following induction chemotherapy in Acute Myeloid Leukemia: Experience from a comprehensive cancer center in Latin America

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJunior Carbajal ChipayoLCLourdes López Chavez

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies induction chemotherapy complications and mortality predictors in acute myeloid leukemia patients, suggesting risk factors impact survival.

Key Points

  • Early mortality in AML patients reached 24.3%, indicating significant risk after induction chemotherapy.
  • Septic shock was the leading cause of death, with pneumonia and bacteremia also prevalent complications.
  • Analysis used Cox proportional hazards regression to identify associations between comorbidities and complications with early mortality.
  • Findings highlight the importance of monitoring infection and performance status in improving outcomes for AML patients.

Cite This Study

Chipayo et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d812https://doi.org/10.1182/blood-2025-2834
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Induction mortality in acute leukemia: The hidden burden of infections in a middle-income country2025
  2. 2Predictors of early mortality in Acute Myeloid Leukemia: A population based analysis using SEER data.2025
  3. 3Acute myeloid leukemia outcome in developing countries: a single center experience as an example in patients aged less than 60 years2025
  4. 4Hematologic predictors of serious infection and impact of serious infection on long-term mortality in AML patients: Insights from propensity-matched real-world cohorts2025
  5. 5Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax2025